Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.
Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.
Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.
The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.
Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.
The agreement was first announced in October.
Shares of Monte Rosa jumped over 8% in recent Wednesday premarket activity, while Novartis' stock edged up by 0.1%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。